Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Dyadic International, Inc.NASDAQ: DYAI

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $791.84K rose 166.0% year over year, ahead of the +51.7% change in trailing-twelve-month cost of revenue. Sequentially, it rose 105.9% from the prior quarter. Over 3 fiscal years it compounded at +3.0% a year.

Context

  • Cost of revenue amounted to 188.3% of revenue in FY2025, up 154.1 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +166.0% holds above the trailing-twelve-month pace of +51.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$791.84K+105.9% QoQ
Last fiscal yearDec 2025
$2.32M+94.2% YoY
LTMMar 2026
$2.04M+51.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+166.0%——
1 year+94.2%——
3-year CAGR+3.0%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
2.32M USD
Year-over-year change
+94.2%
4-year CAGR
+4.5%

Cost of Revenue vs competitors

How DYAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +51.7% is the 2nd highest of 5, against a peer median of -49.0%.
  • Cost of revenue amounts to 68.7% of revenue for DYAI, versus a peer median of 21.3%.
DYAI Competitors
Cost of Revenue for DYAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$6.36M USD-57.6%-31.4%24.0%
DYAIDyadic International, Inc.LTM Mar 2026$2.04M USD+51.7%+3.0%68.7%
RNXTRenovoRx, Inc.LTM Mar 2026$317K USD+237.2%—21.3%
ATHEAlterity Therapeutics LimitedFY2025A$127.52K AUD-40.5%-29.5%2.3%
VERUVeru Inc.LTM Mar 2026$86.1K USD-98.7%——
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$0 USD———
PYPDPolyPid Ltd.LTM Mar 2026$0 USD———
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 USD———
Peer median (excluding DYAI) —-49.0%-30.4%21.3%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.4M2.93M2.9M3.5M1.23M
Cost of Revenue1.94M2.12M1.98M1.19M2.32M
Gross Profit459.39K807.11K922.96K2.3M(1.09M)
Gross Margin19.1%27.5%31.8%65.8%-88.3%
Research & Development8.39M4.5M3.3M2.04M2.15M
Selling, General & Admin6.7M6.42M5.82M6.13M5.76M
Operating Expenses15.19M10.97M9.15M8.2M6.06M
Depreciation & Amortization3.49M038.42K00
EBITDA(11.14M)(10.12M)(8.15M)(5.38M)(6.91M)
EBITDA Margin-463.4%-345.2%-281.3%-154.0%-560.6%
Operating Income(14.73M)(10.17M)(8.23M)(5.9M)(7.15M)
Operating Margin-612.7%-346.9%-283.9%-168.8%-579.9%
Interest Income51.7K180.42K416.69K456.99K284.09K
Interest Expense000427.97K455.9K
Other Income / Expenses1.66M430.42K1.43M91.66K(218.71K)
Income Before Tax(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Pre-Tax Margin-543.7%-332.2%-234.4%-166.2%-597.6%
Income Tax Expense00000
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Net Margin-543.7%-332.2%-234.4%-166.2%-597.6%
EPS (Basic)(0.47)(0.34)(0.24)(0.20)(0.23)
EPS (Diluted)(0.47)(0.34)(0.24)(0.20)(0.23)
Weighted Avg Shares27.84M28.36M28.8M29.32M32.62M
Weighted Avg Shares (Diluted)27.84M28.36M28.8M29.32M32.62M

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.